Brokerages forecast that Hill-Rom Holdings, Inc. (NYSE:HRC) will announce $1.11 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Hill-Rom’s earnings, with estimates ranging from $1.10 to $1.12. Hill-Rom reported earnings of $1.05 per share in the same quarter last year, which suggests a positive year over year growth rate of 5.7%. The firm is scheduled to announce its next earnings report before the market opens on Friday, April 26th.
On average, analysts expect that Hill-Rom will report full year earnings of $5.04 per share for the current financial year, with EPS estimates ranging from $5.02 to $5.07. For the next year, analysts expect that the business will report earnings of $5.70 per share, with EPS estimates ranging from $5.61 to $5.79. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Hill-Rom.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings data on Friday, January 25th. The medical technology company reported $1.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.98 by $0.04. Hill-Rom had a net margin of 7.21% and a return on equity of 21.23%. The company had revenue of $683.50 million during the quarter, compared to the consensus estimate of $676.39 million. During the same quarter last year, the company earned $0.92 earnings per share. Hill-Rom’s revenue for the quarter was up 2.1% on a year-over-year basis.
Several equities analysts have recently commented on HRC shares. ValuEngine upgraded Hill-Rom from a “hold” rating to a “buy” rating in a research note on Saturday, January 19th. Morgan Stanley reduced their target price on Hill-Rom from $100.00 to $98.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. Needham & Company LLC reiterated a “buy” rating and set a $116.00 target price on shares of Hill-Rom in a research note on Monday, March 11th. Zacks Investment Research upgraded Hill-Rom from a “hold” rating to a “buy” rating and set a $118.00 target price for the company in a research note on Tuesday. Finally, Barclays increased their target price on Hill-Rom from $103.00 to $108.00 and gave the company an “equal weight” rating in a research note on Monday, April 15th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $109.88.
Shares of NYSE:HRC opened at $95.62 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.70 and a quick ratio of 1.25. Hill-Rom has a 52-week low of $81.82 and a 52-week high of $108.68. The company has a market capitalization of $6.37 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 1.82 and a beta of 0.95.
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 22nd were paid a dividend of $0.21 per share. The ex-dividend date of this dividend was Thursday, March 21st. This is a boost from Hill-Rom’s previous quarterly dividend of $0.20. This represents a $0.84 annualized dividend and a yield of 0.88%. Hill-Rom’s dividend payout ratio (DPR) is 17.68%.
A number of institutional investors and hedge funds have recently made changes to their positions in HRC. Oregon Public Employees Retirement Fund lifted its stake in Hill-Rom by 8,755.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,308,056 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 2,281,991 shares during the last quarter. Norges Bank acquired a new position in shares of Hill-Rom during the fourth quarter valued at $66,335,000. Bank of New York Mellon Corp increased its holdings in shares of Hill-Rom by 27.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,038,521 shares of the medical technology company’s stock valued at $91,961,000 after purchasing an additional 220,981 shares during the period. BlackRock Inc. increased its holdings in shares of Hill-Rom by 3.5% during the fourth quarter. BlackRock Inc. now owns 6,350,899 shares of the medical technology company’s stock valued at $562,371,000 after purchasing an additional 215,770 shares during the period. Finally, Marshall Wace LLP increased its holdings in shares of Hill-Rom by 179.2% during the third quarter. Marshall Wace LLP now owns 332,231 shares of the medical technology company’s stock valued at $31,363,000 after purchasing an additional 213,243 shares during the period. Hedge funds and other institutional investors own 85.15% of the company’s stock.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: Using other technical indicators with support levels
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.